volume 9 issue 10 pages 3814-38150000

Access barriers to epinephrine autoinjectors for the treatment of anaphylaxis: A survey of practitioners

Punita Ponda 1
Anne F Russell 2
Joyce E. Yu 3
Michael H Land 4
Maria G Crain 5
Kiran Patel 6
Jodi A. Shroba 7
Panida Sriaroon 8
1
 
Division of Allergy and Immunology, Department of Pediatrics, Cohen Children’s Medical Center of New York, Donald Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
4
 
Allergy Department, Southern California Permanente Medical Group, San Diego, Calif
6
 
Division of Pulmonology, Allergy, Cystic Fibrosis, and Sleep Medicine, Department of Pediatrics, Children’s Healthcare of Atlanta, Atlanta, Ga
7
 
Division of Allergy and Immunology. Children’s Mercy Hospital, Kansas City, Mo
Publication typeJournal Article
Publication date2021-10-01
scimago Q1
wos Q1
SJR1.834
CiteScore11.0
Impact factor6.6
ISSN22132198, 22132201
Immunology and Allergy
Abstract
Epinephrine is the first-line treatment for systemic allergic reactions including anaphylaxis and commonly prescribed for self-administration as an epinephrine autoinjector (EAI).1 More EAI prescriptions have been written during the past decade, with an annualized growth of 8% between 2004 and 2010.2 The 2016 U.S. congressional hearings reported considerable EAI price hikes coupled with increased demand.3 Although the U.S. Food and Drug Administration first noted EAI shortages in May 2018, shortages are ongoing, directly impacting patient care.
Found 
Found 

Top-30

Publishers

1
2
3
Elsevier
3 publications, 42.86%
Wiley
2 publications, 28.57%
Springer Nature
1 publication, 14.29%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
7
Share
Cite this
GOST |
Cite this
GOST Copy
Ponda P. et al. Access barriers to epinephrine autoinjectors for the treatment of anaphylaxis: A survey of practitioners // Journal of Allergy and Clinical Immunology: In Practice. 2021. Vol. 9. No. 10. pp. 3814-38150000.
GOST all authors (up to 50) Copy
Ponda P., Russell A. F., Yu J. E., Land M. H., Crain M. G., Patel K., Shroba J. A., Sriaroon P. Access barriers to epinephrine autoinjectors for the treatment of anaphylaxis: A survey of practitioners // Journal of Allergy and Clinical Immunology: In Practice. 2021. Vol. 9. No. 10. pp. 3814-38150000.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.jaip.2021.05.028
UR - https://doi.org/10.1016/j.jaip.2021.05.028
TI - Access barriers to epinephrine autoinjectors for the treatment of anaphylaxis: A survey of practitioners
T2 - Journal of Allergy and Clinical Immunology: In Practice
AU - Ponda, Punita
AU - Russell, Anne F
AU - Yu, Joyce E.
AU - Land, Michael H
AU - Crain, Maria G
AU - Patel, Kiran
AU - Shroba, Jodi A.
AU - Sriaroon, Panida
PY - 2021
DA - 2021/10/01
PB - Elsevier
SP - 3814-38150000
IS - 10
VL - 9
PMID - 34126272
SN - 2213-2198
SN - 2213-2201
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Ponda,
author = {Punita Ponda and Anne F Russell and Joyce E. Yu and Michael H Land and Maria G Crain and Kiran Patel and Jodi A. Shroba and Panida Sriaroon},
title = {Access barriers to epinephrine autoinjectors for the treatment of anaphylaxis: A survey of practitioners},
journal = {Journal of Allergy and Clinical Immunology: In Practice},
year = {2021},
volume = {9},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1016/j.jaip.2021.05.028},
number = {10},
pages = {3814--38150000},
doi = {10.1016/j.jaip.2021.05.028}
}
MLA
Cite this
MLA Copy
Ponda, Punita, et al. “Access barriers to epinephrine autoinjectors for the treatment of anaphylaxis: A survey of practitioners.” Journal of Allergy and Clinical Immunology: In Practice, vol. 9, no. 10, Oct. 2021, pp. 3814-38150000. https://doi.org/10.1016/j.jaip.2021.05.028.